JMP Securities Reiterates Market Outperform on CureVac, Maintains $16 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Roy Buchanan has reiterated a Market Outperform rating for CureVac (NASDAQ:CVAC) and maintained a price target of $16.
September 16, 2024 | 2:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities has reiterated its Market Outperform rating for CureVac, maintaining a $16 price target. This suggests confidence in CureVac's potential for growth.
The reiteration of a Market Outperform rating and maintenance of a $16 price target by JMP Securities indicates a positive outlook for CureVac. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100